Visionary Wealth Advisors raised its stake in Johnson & Johnson (NYSE: JNJ – Get Rating) by 1.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 48,833 shares of the company stock after purchasing an additional 676 shares during the period. Visionary Wealth Advisors’ holdings in Johnson & Johnson were worth $ 8,354,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Family CFO Inc bought a new stake in Johnson & Johnson in the fourth quarter valued at $ 26,000. Steward Financial Group LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth about $ 34,000. Iron Horse Wealth Management LLC increased its position in shares of Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock worth $ 45,000 after acquiring an additional 61 shares in the last quarter. Gibson Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth about $ 49,000. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Johnson & Johnson by 290.7% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock worth $ 47,000 after acquiring an additional 218 shares in the last quarter. 68.78% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently commented on the stock. The Goldman Sachs Group boosted their target price on shares of Johnson & Johnson from $ 163.00 to $ 181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Bank of America assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, March 2nd. They set a “neutral” rating for the company. Raymond James boosted their target price on shares of Johnson & Johnson from $ 195.00 to $ 196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Citigroup reduced their price objective on shares of Johnson & Johnson from $ 210.00 to $ 205.00 in a research report on Tuesday, May 17th. Finally, Credit Suisse Group upped their price target on shares of Johnson & Johnson from $ 200.00 to $ 205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $ 190.50.
Shares of JNJ stock opened at $ 170.08 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The company has a market capitalization of $ 447.55 billion, a price-to-earnings ratio of 22.92, a PEG ratio of 3.41 and a beta of 0.66. Johnson & Johnson has a 52-week low of $ 155.72 and a 52-week high of $ 186.69. The company has a 50-day simple moving average of $ 178.35 and a two-hundred day simple moving average of $ 172.69.
Johnson & Johnson (NYSE: JNJ – Get Rating) last released its earnings results on Tuesday, April 19th. The company reported $ 2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $ 2.60 by $ 0.07. The firm had revenue of $ 23.43 billion for the quarter, compared to analysts’ expectations of $ 23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the company earned $ 2.59 earnings per share. On average, sell-side analysts forecast that Johnson & Johnson will post 10.23 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were paid a $ 1.13 dividend. This represents a $ 4.52 dividend on an annualized basis and a yield of 2.66%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $ 1.06. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s payout ratio is presently 60.92%.
In related news, EVP Kathryn E. Wengel sold 40,000 shares of the company stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $ 173.00, for a total transaction of $ 6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $ 12,336,803. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Hait sold 29,699 shares of the company stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $ 183.58, for a total transaction of $ 5,452,142.42. Following the sale, the insider now owns 80,236 shares in the company, valued at $ 14,729,724.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 78,161 shares of company stock worth $ 13,895,302. Corporate insiders own 0.35% of the company stock.
Johnson & Johnson Company Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.